Affiliated Hospital of Southwest Jiaotong University, Chengdu 610036, China.
Department of Pathology, The Third People’s Hospital of Chengdu, Chengdu 610031, China.
Aging (Albany NY). 2020 Oct 22;12(20):20778-20800. doi: 10.18632/aging.104014.
Long noncoding RNAs (lncRNAs) have been proposed as diagnostic or prognostic biomarkers of head and neck squamous carcinoma (HNSCC). The current study aimed to develop a lncRNA-based prognostic nomogram for HNSCC. LncRNA expression profiles were downloaded from The Cancer Genome Atlas (TCGA) database. After the reannotation of lncRNAs, the differential analysis identified 253 significantly differentially expressed lncRNAs in training set TCGA-HNSC (n = 300). The prognostic value of each lncRNA was first estimated in univariate Cox analysis, and 41 lncRNAs with P < 0.05 were selected as seed lncRNAs for Cox LASSO regression, which identified 11 lncRNAs. Multivariate Cox analysis was used to establish an 8-lncRNA signature with prognostic value. Patients in the high-signature score group exhibited a significantly worse overall survival (OS) than those in the low-signature score group, and the area under the receiver operating characteristic (ROC) curve for 3-year survival was 0.74. Multivariable Cox regression analysis among the clinical characteristics and signature scores suggested that the signature is an independent prognostic factor. The internal validation cohort, external validation cohort, and 102 HNSCC specimens quantified by qRT-PCR successfully validate the robustness of our nomogram.
长链非编码 RNA(lncRNA)被认为是头颈部鳞状细胞癌(HNSCC)的诊断或预后生物标志物。本研究旨在开发基于 lncRNA 的 HNSCC 预后列线图。从癌症基因组图谱(TCGA)数据库中下载 lncRNA 表达谱。在 lncRNA 的重新注释后,差异分析鉴定出训练集 TCGA-HNSC(n=300)中 253 个显著差异表达的 lncRNA。首先在单变量 Cox 分析中估计每个 lncRNA 的预后价值,并且选择 P<0.05 的 41 个 lncRNA 作为 Cox LASSO 回归的种子 lncRNA,确定了 11 个 lncRNA。多变量 Cox 分析用于建立具有预后价值的 8-lncRNA 特征。高特征评分组的患者总生存期(OS)明显差于低特征评分组,并且 3 年生存率的受试者工作特征(ROC)曲线下面积为 0.74。临床特征和特征评分之间的多变量 Cox 回归分析表明,该特征是一个独立的预后因素。内部验证队列、外部验证队列和通过 qRT-PCR 定量的 102 个 HNSCC 标本成功验证了我们的列线图的稳健性。
Front Oncol. 2021-12-23
Front Immunol. 2021-12-24